Company Overview and News

 
Don’t bar parties from owning media companies

2018-10-09 theedgemarkets
KUALA LUMPUR: Political parties should not be prevented from owning media companies and should be free to compete for readers, said The Edge Communications Sdn Bhd publisher and group chief executive officer Ho Kay Tat.
4502 MIAHF

 
Don’t bar political parties from owning media: Publisher

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): Political parties should not be prevented from owning media companies and should be free to compete for readers, says The Edge Communications Sdn Bhd publisher and group chief executive officer Ho Kay Tat.
4502 MIAHF

 
Cover Story: Hazy prospects for media companies

2018-10-04 theedgemarkets
ALTHOUGH Star Media Group Bhd is currently not in its best financial state, the fact that it is still turning a profit sets it a cut above other struggling Bursa Malaysia-listed media companies. Many print-based media firms, not only those in Malaysia, are trying hard to stay afloat.
4502 5754 MIAHF 6025 MS

 
In a New Malaysia, a veteran newsman returns to head Media Prima’s news operations

2018-10-02 malaymail
KUALA LUMPUR, Oct 2 — The return of veteran newsman Mustapha Kamil Mohd Janor to New Straits Times is the latest “comeback” in a year celebrating comebacks.
4502 MIAHF

 
Media Prima: Mustapha Kamil appointed as executive director

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): Media Prima Bhd announced today Mustapha Kamil Mohd Janor's appointment as executive director, news and editorial, and he will be responsible for the overall operations of the group's news and editorial functions.
4502 MIAHF

 
Independent journalism seen to benefit media firms in long term

2018-10-01 theedgemarkets
Media sector Maintain neutral: The Malaysian Insight on Sept 6 reported, citing sources, that Prime Minister Tun Dr Mahathir Mohamad was mulling a ruling to cap political parties’ ownership of mainstream media companies at 10%.
4502 5754 6084 MIAHF

 
Improving national fund manager’s future

2018-09-29 thestar.com.my
THERE is great interest in how Tan Sri Zeti Akhtar Aziz will perform as the chairman of Permodalan Nasional Bhd (PNB). Any doubts from the public engagement perspective, however, were soon cast aside as the ease and confidence of her message was second nature for a person once named the world’s best central banker.
4502 MIAHF

 
Better q-o-q, weaker y-o-y results expected for Astro 2Q

2018-09-26 theedgemarkets
Astro Malaysia Holdings Bhd (Sept 25, RM1.66) Maintain hold with an unchanged target price (TP) of RM2.02: Astro Malaysia Holdings Bhd’s second quarter of financial year ended July 31, 2018 (2QFY19) results are scheduled to be announced today and we expect it to be a stronger quarter-on-quarter (q-o-q) and weaker year-on-year (y-o-y) to match our core net profit expectations of around RM190 million to RM200 million.
4502 MIAHF 6399

 
Media Prima partners Ziff Davis to offer new Mashable site in Malaysia

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Media Prima Bhd's wholly-owned subsidiary Rev Asia Holdings Sdn Bhd has entered into an agreement with US-based digital media company Ziff Davis LLC to operate Mashable Southeast Asia (sea.mashable.com) for audiences across Indonesia, Malaysia, the Philippines and Singapore.
4502 MIAHF 0173

 
Rising jet fuel price woes

2018-09-15 thestar.com.my
IT’S certainly a big deal for Malaysia Airlines Bhd (MAS) to report higher losses of RM812mil for its financial year 2017. This compares with the RM439mil loss recorded in 2016 and the whopping RM1.13bil loss in 2015.
4502 MIAHF MS BSMAF 1818

 
Will curbs on politicians owning media target proxies too? Journalists’ group asks

2018-09-11 malaymail
PETALING JAYA, Sept 11 — Press groups have raised various concerns about the government’s proposal to cap share ownership in media organisations by political parties.
4502 5754 6084 MIAHF

 
Umno’s media assets dilemma

2018-09-08 thestar.com.my
Troubled industry: Utusan Melayu, which publishes the Utusan Malaysia newspaper, is facing the possibility of being de-listed, while Media Prima has begun selling its prized assets.
4502 5754 MIAHF MS BSMAF 1818

 
PNB arrangement seen unlocking Media Prima’s property value

2018-09-04 theedgemarkets
Media Prima Bhd (Sept 3, 45 sen) Maintain neutral with a higher target price of 49 sen: Media Prima Bhd’s second quarter of the financial year ended June 30, 2018 (2QFY18) revenue grew 4.1% year-on-year (y-o-y), mainly driven by higher digital advertising and home shopping revenue. The group reduced its reliance on traditional businesses from 88% in the first half of FY17 (1HFY17) to 77% in 1HFY18.
4502 MIAHF 0173

 
Media Prima rises after reporting 2Q, 1H profit

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): Media Prima Bhd shares rose as much as five sen or 12% to 46 sen so far today after the group said on Thursday it posted a net profit of RM31.95 million in the second quarter ended June 30, 2018 (2QFY18) from a net loss of RM132.91 million a year earlier.
4502 MIAHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...